- Home
- TNON vs LPTX Comparison
TNON vs LPTX Comparison
Compare TNON & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- LPTX
- Stock Information
- Founded
- TNON 2012
- LPTX 2011
- Country
- TNON United States
- LPTX United States
- Employees
- TNON N/A
- LPTX N/A
- Industry
- TNON Medical Specialities
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNON Health Care
- LPTX Health Care
- Exchange
- TNON Nasdaq
- LPTX Nasdaq
- Market Cap
- TNON 11.5M
- LPTX 11.1M
- IPO Year
- TNON 2022
- LPTX N/A
- Fundamental
- Price
- TNON $1.17
- LPTX $0.31
- Analyst Decision
- TNON Strong Buy
- LPTX Hold
- Analyst Count
- TNON 2
- LPTX 1
- Target Price
- TNON $5.50
- LPTX N/A
- AVG Volume (30 Days)
- TNON 269.5K
- LPTX 710.1K
- Earning Date
- TNON 11-12-2025
- LPTX 11-12-2025
- Dividend Yield
- TNON N/A
- LPTX N/A
- EPS Growth
- TNON N/A
- LPTX N/A
- EPS
- TNON N/A
- LPTX N/A
- Revenue
- TNON $2,947,000.00
- LPTX N/A
- Revenue This Year
- TNON $43.52
- LPTX N/A
- Revenue Next Year
- TNON $82.14
- LPTX N/A
- P/E Ratio
- TNON N/A
- LPTX N/A
- Revenue Growth
- TNON N/A
- LPTX N/A
- 52 Week Low
- TNON $0.85
- LPTX $0.22
- 52 Week High
- TNON $7.51
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- TNON 44.55
- LPTX 55.37
- Support Level
- TNON $1.13
- LPTX $0.28
- Resistance Level
- TNON $1.26
- LPTX $0.29
- Average True Range (ATR)
- TNON 0.07
- LPTX 0.02
- MACD
- TNON -0.01
- LPTX 0.00
- Stochastic Oscillator
- TNON 26.09
- LPTX 79.89
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.